Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 105

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 105
---
 our customer base; (ii) continue to implement and successfully execute our business and marketing strategy; (iii) successfully enter into other strategic collaborations or relationships; (iv) obtain access to capital on acceptable terms and effectively utilize that capital; identify, attract, hire, retain, motivate and successfully integrate employees; (v) continue to expand, automate and upgrade our laboratory, technology and data systems; (vi) obtain, maintain and expand coverage and reimbursement by healthcare payers; (vii) obtain and maintain sufficient payment by partners, institutions and individuals; (viii) provide rapid test turnaround times with accurate results at low prices; (ix) provide superior customer service; and (x) respond to competitive developments, among other things. We cannot assure you that we will be successful in addressing these risks, and the failure to do so could have an adverse impact on our business, financial condition, results of operations and growth prospects. We face intense competition and may not be able to compete successfully with existing or new competitors in our industry. With the development of next generation sequencing, the clinical genetics market is becoming increasingly competitive and we expect this competition to intensify significantly in the next five to ten years. We face competition from a variety of sources, including: •companies such as Synlab; Centogene N.V.; Invitae Corporation; Mendelics Análise Genômica S.A., Diagnósticos da América S.A.; Igenomix S.L.; Nimgenetics Genómica Y Medicina, S.L.; Color Health, Inc.; Bitgenia Brasil Ltda.; Biomakers S.A.; Argenetics Semillas S.A.; Argenomics S.A.; Genda S.A.; Genos S.A.; Biocodices S.A.; Diagnóstico Maipú por Imágenes S.A.; Viome Life Sciences, Inc; Zoe Limited; 23andMe, Inc.; Ambry Genetics Corporation, a subsidiary of Realm IDx, Inc.; Athena Diagnostics, Inc. and Blueprint Genetics, subsidiaries of Quest Diagnostics Incorporated; Baylor -MiracaGenetics Laboratories LLC; Centogene AG; Connective Tissue Gene Test LLC, a subsidiary of Health Network Laboratories, L.P.; Cooper Surgical, Inc.; Emory Genetics Laboratory, a subsidiary of Eurofins Scientific; Exact Sciences Corporation; Foundation Medicine, Inc., a subsidiary of Roche Holding AG; Freenome Holding, Inc.; Fulgent Genetics, Inc.; GeneDx Holdings Corp; Guardant Health, Inc.; Integrated